Further bolstering the companies' hopes that the withdrawn multiple sclerosis drug Tysabri might one day become available again, Biogen Idec Inc. and Elan Corp. plc disclosed full two-year data from their Phase III monotherapy trial with the compound. (BioWorld Today)